Michael Gold to Male
This is a "connection" page, showing publications Michael Gold has written about Male.
Connection Strength
3.097
-
The cost of non-response to cardiac resynchronization therapy: characterizing heart failure events following cardiac resynchronization therapy. Europace. 2021 10 09; 23(10):1586-1595.
Score: 0.042
-
Impact of age on catheter ablation of premature ventricular contractions. J Cardiovasc Electrophysiol. 2021 04; 32(4):1077-1084.
Score: 0.040
-
Primary Results From the Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) Trial. Circulation. 2021 01 05; 143(1):7-17.
Score: 0.039
-
The ECG Belt for CRT response trial: Design and clinical protocol. Pacing Clin Electrophysiol. 2020 10; 43(10):1063-1071.
Score: 0.038
-
1-Year Prospective Evaluation of Clinical Outcomes and Shocks: The?Subcutaneous?ICD?Post?Approval Study. JACC Clin Electrophysiol. 2020 11; 6(12):1537-1550.
Score: 0.038
-
Relationship of Shock Energy to Impedance During Subcutaneous Implantable Cardioverter-Defibrillator Testing. Circ Arrhythm Electrophysiol. 2020 09; 13(9):e008631.
Score: 0.038
-
Outcomes of subcutaneous implantable cardioverter-defibrillator in dialysis patients: Results from the S-ICD post-approval study. Heart Rhythm. 2020 09; 17(9):1566-1574.
Score: 0.038
-
Electromagnetic interference from left ventricular assist devices in patients with subcutaneous implantable cardioverter-defibrillators. J Cardiovasc Electrophysiol. 2020 05; 31(5):1195-1201.
Score: 0.037
-
Comparison of measures of ventricular delay on cardiac resynchronization therapy response. Heart Rhythm. 2020 04; 17(4):615-620.
Score: 0.036
-
The effect of posture, exercise, and atrial pacing on atrioventricular conduction in systolic heart failure. J Cardiovasc Electrophysiol. 2019 12; 30(12):2892-2899.
Score: 0.036
-
Understanding Outcomes with the EMBLEM S-ICD in Primary Prevention Patients with Low EF Study (UNTOUCHED): Clinical characteristics and perioperative results. Heart Rhythm. 2019 11; 16(11):1636-1644.
Score: 0.035
-
Effect of Interventricular Electrical Delay on Atrioventricular Optimization for Cardiac Resynchronization Therapy. Circ Arrhythm Electrophysiol. 2018 08; 11(8):e006055.
Score: 0.033
-
Acute biventricular hemodynamic effects of cardiac resynchronization therapy in right bundle branch block. Heart Rhythm. 2018 10; 15(10):1525-1532.
Score: 0.033
-
Use of antibiotic envelopes to prevent cardiac implantable electronic device infections: A meta-analysis. J Cardiovasc Electrophysiol. 2018 04; 29(4):609-615.
Score: 0.032
-
The role of interventricular conduction delay to predict clinical response with cardiac resynchronization therapy. Heart Rhythm. 2017 12; 14(12):1748-1755.
Score: 0.032
-
Subcutaneous implantable cardioverter-defibrillator Post-Approval Study: Clinical characteristics and perioperative results. Heart Rhythm. 2017 10; 14(10):1456-1463.
Score: 0.031
-
Impact of Renal Function on Survival After Cardiac Resynchronization Therapy. Am J Cardiol. 2017 Jul 15; 120(2):262-266.
Score: 0.030
-
The Impact of the PR Interval in Patients?Receiving Cardiac Resynchronization Therapy: Results From the REVERSE Study. JACC Clin Electrophysiol. 2017 08; 3(8):818-826.
Score: 0.030
-
The Rap1-cofilin-1 pathway coordinates actin reorganization and MTOC polarization at the B cell immune synapse. J Cell Sci. 2017 03 15; 130(6):1094-1109.
Score: 0.030
-
The Design of the Understanding Outcomes with the S-ICD in Primary Prevention Patients with Low EF Study (UNTOUCHED). Pacing Clin Electrophysiol. 2017 Jan; 40(1):1-8.
Score: 0.030
-
The Effect of Chronic Kidney Disease on Mortality with Cardiac Resynchronization Therapy. Pacing Clin Electrophysiol. 2016 Aug; 39(8):863-9.
Score: 0.029
-
Impact of magnetic resonance imaging on ventricular tachyarrhythmia sensing: Results of the Evera MRI Study. Heart Rhythm. 2016 08; 13(8):1631-5.
Score: 0.029
-
Vagus Nerve Stimulation for the Treatment of Heart Failure: The INOVATE-HF Trial. J Am Coll Cardiol. 2016 07 12; 68(2):149-58.
Score: 0.028
-
Long-Term Extrapolation of Clinical Benefits Among Patients With Mild Heart Failure Receiving Cardiac Resynchronization Therapy: Analysis of the 5-Year Follow-Up From the REVERSE Study. JACC Heart Fail. 2015 Sep; 3(9):691-700.
Score: 0.027
-
Full-Body MRI in Patients With an Implantable Cardioverter-Defibrillator: Primary Results of a Randomized Study. J Am Coll Cardiol. 2015 Jun 23; 65(24):2581-2588.
Score: 0.027
-
Are leadless pacemakers a niche or the future of device therapy? J Am Coll Cardiol. 2015 Apr 21; 65(15):1505-8.
Score: 0.027
-
The effect of reverse remodeling on long-term survival in mildly symptomatic patients with heart failure receiving cardiac resynchronization therapy: results of the REVERSE study. Heart Rhythm. 2015 Mar; 12(3):524-530.
Score: 0.026
-
Use of a discrimination algorithm to reduce inappropriate shocks with a subcutaneous implantable cardioverter-defibrillator. Heart Rhythm. 2014 Aug; 11(8):1352-8.
Score: 0.025
-
The effect of left ventricular electrical delay on the acute hemodynamic response with cardiac resynchronization therapy. J Cardiovasc Electrophysiol. 2014 Jun; 25(6):624-30.
Score: 0.024
-
Implantable defibrillators improve survival in patients with mildly symptomatic heart failure receiving cardiac resynchronization therapy: analysis of the long-term follow-up of remodeling in systolic left ventricular dysfunction (REVERSE). Circ Arrhythm Electrophysiol. 2013 Dec; 6(6):1163-8.
Score: 0.024
-
How many transvenous coils are optimal for defibrillators: one, two, or none? Heart Rhythm. 2013 Jul; 10(7):977-8.
Score: 0.023
-
Influence of intracardiac pressure on spontaneous ventricular arrhythmias in patients with systolic heart failure: insights from the REDUCEhf trial. Circ Arrhythm Electrophysiol. 2013 Apr; 6(2):272-8.
Score: 0.023
-
The effect of left ventricular electrical delay on AV optimization for cardiac resynchronization therapy. Heart Rhythm. 2013 Jul; 10(7):988-93.
Score: 0.023
-
Safety of continuous anticoagulation with dabigatran during implantation of cardiac rhythm devices. Am J Cardiol. 2013 Apr 15; 111(8):1165-8.
Score: 0.023
-
Comparison of fixed tilt and tuned defibrillation waveforms: the PROMISE study. J Cardiovasc Electrophysiol. 2013 Mar; 24(3):323-7.
Score: 0.022
-
Atrial support pacing in heart failure: results from the multicenter PEGASUS CRT trial. J Cardiovasc Electrophysiol. 2012 Dec; 23(12):1317-25.
Score: 0.022
-
Effect of QRS duration and morphology on cardiac resynchronization therapy outcomes in mild heart failure: results from the Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) study. Circulation. 2012 Aug 14; 126(7):822-9.
Score: 0.022
-
Hemoglobin spectroscopy to evaluate hemodynamic function during tachycardias: the future of ICD discrimination algorithms? Heart Rhythm. 2012 Oct; 9(10):1592-3.
Score: 0.022
-
Acute performance of a right ventricular automatic pacing threshold algorithm for implantable defibrillators. Pacing Clin Electrophysiol. 2012 Mar; 35(3):259-68.
Score: 0.021
-
Pre-discharge defibrillation testing: clinically important or obsolete? Europace. 2012 Feb; 14(2):155-6.
Score: 0.021
-
Head-to-head comparison of arrhythmia discrimination performance of subcutaneous and transvenous ICD arrhythmia detection algorithms: the START study. J Cardiovasc Electrophysiol. 2012 Apr; 23(4):359-66.
Score: 0.021
-
Prospective comparison of discrimination algorithms to prevent inappropriate ICD therapy: primary results of the Rhythm ID Going Head to Head Trial. Heart Rhythm. 2012 Mar; 9(3):370-7.
Score: 0.021
-
The relationship between ventricular electrical delay and left ventricular remodelling with cardiac resynchronization therapy. Eur Heart J. 2011 Oct; 32(20):2516-24.
Score: 0.021
-
Modeling Alzheimer's disease progression using the disease system analysis approach. Alzheimers Dement. 2012 Jan; 8(1):39-50.
Score: 0.020
-
Temporal stability of defibrillation thresholds with cardiac resynchronization therapy. Heart Rhythm. 2011 Jul; 8(7):1008-13.
Score: 0.020
-
A prospective, randomized comparison of the acute hemodynamic effects of biventricular and left ventricular pacing with cardiac resynchronization therapy. Heart Rhythm. 2011 May; 8(5):685-91.
Score: 0.020
-
The impact of cardiac resynchronization therapy on the incidence of ventricular arrhythmias in mild heart failure. Heart Rhythm. 2011 May; 8(5):679-84.
Score: 0.020
-
Defibrillation thresholds in hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol. 2011 May; 22(5):569-72.
Score: 0.020
-
Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord. 2010; 30(2):131-46.
Score: 0.019
-
Response to Coceani: Has CRT earned a class I recommendation? Circ Heart Fail. 2010 Jul; 3(4):559-60.
Score: 0.019
-
Randomized comparison of defibrillation thresholds from the right ventricular apex and outflow tract. Heart Rhythm. 2010 Nov; 7(11):1561-6.
Score: 0.019
-
Role of transesophageal echocardiography among patients with atrial fibrillation undergoing electrophysiology testing. Am J Cardiol. 2009 Nov 01; 104(9):1256-8.
Score: 0.018
-
Acute hemodynamic effects of atrial pacing with cardiac resynchronization therapy. J Cardiovasc Electrophysiol. 2009 Aug; 20(8):894-900.
Score: 0.017
-
Role of cardiac resynchronization therapy in asymptomatic and mildly symptomatic heart failure. Curr Heart Fail Rep. 2009 Mar; 6(1):44-8.
Score: 0.017
-
Disparities in preferences for receiving support and education among patients with implantable cardioverter defibrillators. Pacing Clin Electrophysiol. 2009 Mar; 32(3):383-90.
Score: 0.017
-
The effect of dofetilide on ventricular defibrillation thresholds. Pacing Clin Electrophysiol. 2009 Jan; 32(1):24-8.
Score: 0.017
-
Impact of atrial prevention pacing on atrial fibrillation burden: primary results of the Study of Atrial Fibrillation Reduction (SAFARI) trial. Heart Rhythm. 2009 Mar; 6(3):295-301.
Score: 0.017
-
Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2008 Nov 18; 52(21):1718-23.
Score: 0.017
-
Optimization of superior vena cava coil position and usage for transvenous defibrillation. Heart Rhythm. 2008 Mar; 5(3):394-9.
Score: 0.016
-
Atrial overdrive pacing and incidence of heart failure-related adverse events in permanently paced patients. J Interv Card Electrophysiol. 2007 Jun; 19(1):55-60.
Score: 0.015
-
Comparison of defibrillation efficacy and survival associated with right versus left pectoral placement for implantable defibrillators. Am J Cardiol. 2007 Jul 15; 100(2):243-6.
Score: 0.015
-
Dynamic changes of T-wave alternans: does it predict short-term arrhythmia vulnerability? J Cardiovasc Electrophysiol. 2007 May; 18(5):518-9.
Score: 0.015
-
Study design factors and patient demographics and their effect on the decline of placebo-treated subjects in randomized clinical trials in Alzheimer's disease. J Clin Psychiatry. 2007 Mar; 68(3):430-8.
Score: 0.015
-
A prospective comparison of AV delay programming methods for hemodynamic optimization during cardiac resynchronization therapy. J Cardiovasc Electrophysiol. 2007 May; 18(5):490-6.
Score: 0.015
-
Effect of an active abdominal pulse generator on defibrillation thresholds with a dual-coil, transvenous ICD lead system. J Cardiovasc Electrophysiol. 2006 Jun; 17(6):617-20.
Score: 0.014
-
Coronary sinus electrode does not reduce atrial defibrillation thresholds. Heart Rhythm. 2006 Jun; 3(6):647-52.
Score: 0.014
-
Sustained ventricular tachycardia following alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Pacing Clin Electrophysiol. 2005 Dec; 28(12):1354-6.
Score: 0.014
-
Comparison of stimulation sites within left ventricular veins on the acute hemodynamic effects of cardiac resynchronization therapy. Heart Rhythm. 2005 Apr; 2(4):376-81.
Score: 0.013
-
Improved defibrillation efficacy with an ascending ramp waveform in humans. Heart Rhythm. 2005 Apr; 2(4):388-94.
Score: 0.013
-
Clinical predictors of atrial defibrillation thresholds with a dual-coil, active pectoral lead system. Heart Rhythm. 2005 Jan; 2(1):49-54.
Score: 0.013
-
Optimization of atrial defibrillation with a dual-coil, active pectoral lead system. J Cardiovasc Electrophysiol. 2004 Jul; 15(7):790-4.
Score: 0.013
-
The influence of gender on arrhythmias. Cardiol Rev. 2004 Mar-Apr; 12(2):97-105.
Score: 0.012
-
Electrocardiogram and clinical characteristics of patients referred for cardiac transplantation: implications for pacing in heart failure. Clin Cardiol. 2004 Mar; 27(3):151-3.
Score: 0.012
-
Comparison of step-down and binary search algorithms for determination of defibrillation threshold in humans. Pacing Clin Electrophysiol. 2004 Feb; 27(2):218-20.
Score: 0.012
-
Enhanced detection of arrhythmia vulnerability using T wave alternans, left ventricular ejection fraction, and programmed ventricular stimulation: a prospective study in subjects with chronic ischemic heart disease. J Cardiovasc Electrophysiol. 2004 Feb; 15(2):170-6.
Score: 0.012
-
Effect of shock polarity on defibrillation thresholds with a hybrid patch-coil lead system. J Interv Card Electrophysiol. 2003 Dec; 9(3):391-6.
Score: 0.012
-
Distal right ventricular coil position reduces defibrillation thresholds. J Cardiovasc Electrophysiol. 2003 Oct; 14(10):1036-40.
Score: 0.012
-
Treatment of pancreatic pseudoaneurysm with percutaneous transabdominal thrombin injection. J Vasc Surg. 2003 Sep; 38(3):600-2.
Score: 0.012
-
Cardiac Resynchronization Therapy Improves Outcomes in Patients With Intraventricular Conduction Delay But Not Right Bundle Branch Block: A Patient-Level Meta-Analysis of Randomized Controlled Trials. Circulation. 2023 Mar 07; 147(10):812-823.
Score: 0.011
-
Safety of a single successful conversion of ventricular fibrillation before the implantation of cardioverter defibrillators. Pacing Clin Electrophysiol. 2003 Jan; 26(1P2):483-6.
Score: 0.011
-
Randomized Trial of Left Bundle Branch vs Biventricular Pacing for Cardiac Resynchronization Therapy. J Am Coll Cardiol. 2022 09 27; 80(13):1205-1216.
Score: 0.011
-
Influence of QRS duration on the prognostic value of T wave alternans. J Cardiovasc Electrophysiol. 2002 Aug; 13(8):770-5.
Score: 0.011
-
Efficacy and temporal stability of reduced safety margins for ventricular defibrillation: primary results from the Low Energy Safety Study (LESS). Circulation. 2002 Apr 30; 105(17):2043-8.
Score: 0.011
-
Clinical predictors of defibrillation thresholds with an active pectoral pulse generator lead system. Pacing Clin Electrophysiol. 2002 Apr; 25(4 Pt 1):408-13.
Score: 0.011
-
Lack of benefit of an active pectoral pulse generator on atrial defibrillation thresholds. J Cardiovasc Electrophysiol. 2002 Apr; 13(4):332-5.
Score: 0.011
-
Effect of shock polarity on the efficacy of transthoracic atrial defibrillation. Am Heart J. 2002 Mar; 143(3):541-5.
Score: 0.011
-
Effects of selective autonomic blockade on T-wave alternans in humans. Circulation. 2002 Feb 19; 105(7):837-42.
Score: 0.011
-
Comparison of the effects of active left and right pectoral pulse generators on defibrillation efficacy. Am J Cardiol. 2001 Dec 01; 88(11):1308-11.
Score: 0.010
-
A new algorithm for transthoracic cardioversion of atrial fibrillation based on body weight. Am J Cardiol. 2001 Nov 01; 88(9):1043-5.
Score: 0.010
-
Clinical experience with a dual-chamber implantable cardioverter defibrillator to treat atrial tachyarrhythmias. J Cardiovasc Electrophysiol. 2001 Nov; 12(11):1247-53.
Score: 0.010
-
Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination Drug. Am J Clin Dermatol. 2022 Jan; 23(1):93-104.
Score: 0.010
-
Amplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE): A Randomized, Controlled Trial. Circulation. 2021 11 09; 144(19):1543-1552.
Score: 0.010
-
Effects of single-dose L-theanine on motor cortex excitability. Clin Neurophysiol. 2021 09; 132(9):2062-2064.
Score: 0.010
-
Contrast-enhanced image-guided lead deployment for left bundle branch pacing. Heart Rhythm. 2021 08; 18(8):1318-1325.
Score: 0.010
-
Relationship of paced left bundle branch pacing morphology with anatomic location and physiological outcomes. Heart Rhythm. 2021 06; 18(6):946-953.
Score: 0.010
-
Acute Hemodynamic Effects of Cardiac Resynchronization Therapy Versus Alternative Pacing Strategies in Patients With Left Ventricular Assist Devices. J Am Heart Assoc. 2021 03 16; 10(6):e018127.
Score: 0.010
-
Using the years-of-healthy-life measure to calculate QALYs. Am J Prev Med. 2001 Jan; 20(1):35-9.
Score: 0.010
-
Clinical predictors and efficacy of antitachycardia pacing in patients with implantable cardioverter defibrillators: the importance of the patient's sex. Pacing Clin Electrophysiol. 2001 Jan; 24(1):70-4.
Score: 0.010
-
Device-Detected Atrial Fibrillation Before and After Hospitalisation for Noncardiac Surgery or Medical Illness: Insights From ASSERT. Can J Cardiol. 2021 05; 37(5):803-809.
Score: 0.010
-
Effect of second-phase duration on the strength-duration relation for human transvenous defibrillation. Circulation. 2000 Oct 31; 102(18):2239-42.
Score: 0.010
-
IncobotulinumtoxinA Demonstrates Safety and Prolonged Duration of Effect in a Dose-Ranging Study for Glabellar Lines. J Drugs Dermatol. 2020 10 01; 19(10):985-991.
Score: 0.010
-
Permanent His Bundle Pacing Implantation Facilitated by Visualization of the Tricuspid Valve Annulus. Circ Arrhythm Electrophysiol. 2020 10; 13(10):e008370.
Score: 0.010
-
Differences in clinical characteristics and reported quality of life of men and women undergoing cardiac resynchronization therapy. ESC Heart Fail. 2020 10; 7(5):2972-2982.
Score: 0.010
-
Anaphylaxis during insertion of a ventriculoperitoneal shunt. Anesthesiology. 2000 Aug; 93(2):578-9.
Score: 0.010
-
Bilateral Bundle Branch Area Pacing to Achieve Physiological Conduction System Activation. Circ Arrhythm Electrophysiol. 2020 08; 13(8):e008267.
Score: 0.010
-
Active-Fixation Atrial Leads and the Risk of Atrial Fibrillation: Insights From ASSERT. Circ Arrhythm Electrophysiol. 2020 09; 13(9):e008655.
Score: 0.010
-
Developmental outcomes following vaccine-proximate febrile seizures in children. Neurology. 2020 07 21; 95(3):e226-e238.
Score: 0.010
-
Acute hemodynamic effects of right ventricular pacing site and pacing mode in patients with congestive heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 2000 May 01; 85(9):1106-9.
Score: 0.009
-
Short term escape rhythm characteristics after radiofrequency ablation of the atrioventricular junction. J Interv Card Electrophysiol. 2000 Apr; 4(1):301-5.
Score: 0.009
-
Characterization of Upper Gastrointestinal Motility in Infants With Persistent Distress and Non-IgE-mediated Cow's Milk Protein Allergy. J Pediatr Gastroenterol Nutr. 2020 04; 70(4):489-496.
Score: 0.009
-
Intracardiac echocardiography use and outcomes after catheter ablation of ventricular tachycardia. J Comp Eff Res. 2020 04; 9(5):375-385.
Score: 0.009
-
TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma. Nat Med. 2020 04; 26(4):577-588.
Score: 0.009
-
Signal-averaged isoharmonic body surface maps of patients with ischemic cardiomyopathy. J Cardiovasc Electrophysiol. 2000 Feb; 11(2):160-7.
Score: 0.009
-
Sensing lead failure in implantable defibrillators: a comparison of two commonly used leads. J Cardiovasc Electrophysiol. 2000 Jan; 11(1):21-4.
Score: 0.009
-
Optimization of transvenous coil position for active can defibrillation thresholds. J Cardiovasc Electrophysiol. 2000 Jan; 11(1):25-9.
Score: 0.009
-
Real-world outcomes of ventricular tachycardia catheter ablation with versus without intracardiac echocardiography. J Cardiovasc Electrophysiol. 2020 02; 31(2):417-422.
Score: 0.009
-
Evaluation, Management, and Outcomes of Patients Poorly Responsive to Cardiac?Resynchronization Device Therapy. J Am Coll Cardiol. 2019 11 26; 74(21):2588-2603.
Score: 0.009
-
Interaction of septadian and circadian rhythms in life-threatening ventricular arrhythmias in patients with implantable cardioverter-defibrillators. Am J Cardiol. 1999 Sep 01; 84(5):555-7.
Score: 0.009
-
Cardiac arrhythmia: current therapy. Hosp Pract (1995). 1999 Sep 01; 34(9):27-8, 31-2, 35-8 passim.
Score: 0.009
-
A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. Ann Oncol. 2019 09 01; 30(9):1487-1495.
Score: 0.009
-
Atrial defibrillation with a transvenous lead: a randomized comparison of active can shocking pathways. J Am Coll Cardiol. 1999 Aug; 34(2):358-62.
Score: 0.009
-
Comparison of bipolar and integrated sensing for redetection of ventricular fibrillation. Am Heart J. 1999 Jul; 138(1 Pt 1):133-6.
Score: 0.009
-
Plasticity of left ventricular function with cardiac resynchronization therapy. J Interv Card Electrophysiol. 2020 Mar; 57(2):289-294.
Score: 0.009
-
Left bundle branch pacing for symptomatic bradycardia: Implant success rate, safety, and pacing characteristics. Heart Rhythm. 2019 12; 16(12):1758-1765.
Score: 0.009
-
Immediate and persistent complete heart block following a horse kick. Pacing Clin Electrophysiol. 1999 May; 22(5):816-8.
Score: 0.009
-
The effect of procainamide on T wave alternans. J Cardiovasc Electrophysiol. 1999 May; 10(5):649-54.
Score: 0.009
-
Factors Associated With High-Voltage Impedance and Subcutaneous Implantable Defibrillator Ventricular Fibrillation Conversion Success. Circ Arrhythm Electrophysiol. 2019 04; 12(4):e006665.
Score: 0.009
-
Intravenous amiodarone suppression of electrical storm refractory to chronic oral amiodarone. Pacing Clin Electrophysiol. 1999 Apr; 22(4 Pt 1):665-7.
Score: 0.009
-
Overdrive atrial pacing for conversion of atrial flutter: comparison of postoperative with nonpostoperative patients. Am Heart J. 1999 Jan; 137(1):100-3.
Score: 0.009
-
The effect of shock configuration and delivered energy on defibrillation impedance. Pacing Clin Electrophysiol. 1999 Jan; 22(1 Pt 2):165-8.
Score: 0.009
-
A new defibrillator discrimination algorithm utilizing electrogram morphology analysis. Pacing Clin Electrophysiol. 1999 Jan; 22(1 Pt 2):179-82.
Score: 0.009
-
Reversible prolonged pacemaker failure due to electrocautery. J Interv Card Electrophysiol. 1998 Dec; 2(4):343-4.
Score: 0.009
-
A comparison of pectoral and abdominal transvenous defibrillator implantation: analysis of costs and outcomes. J Interv Card Electrophysiol. 1998 Dec; 2(4):345-9.
Score: 0.009
-
Inappropriate shocks from implanted cardioverter defibrillators caused by sensing of diaphragmatic myopotentials. J Interv Card Electrophysiol. 1998 Dec; 2(4):367-70.
Score: 0.009
-
Development of a biomarker panel to predict cardiac resynchronization therapy response: Results from the SMART-AV trial. Heart Rhythm. 2019 05; 16(5):743-753.
Score: 0.009
-
Competitive athletes with implantable cardioverter-defibrillators-How to program? Data from the Implantable Cardioverter-Defibrillator Sports Registry. Heart Rhythm. 2019 04; 16(4):581-587.
Score: 0.008
-
Activation of the Rap1 GTPase by the B cell antigen receptor. J Biol Chem. 1998 Oct 30; 273(44):29218-23.
Score: 0.008
-
Noninvasive tissue adhesive for cardiac implantable electronic device pocket closure: the TAPE pilot study. J Interv Card Electrophysiol. 2019 Mar; 54(2):171-176.
Score: 0.008
-
The effect of delivered energy on defibrillation shock impedance. J Interv Card Electrophysiol. 1998 Sep; 2(3):273-7.
Score: 0.008
-
Effect of heart rate on T wave alternans. J Cardiovasc Electrophysiol. 1998 Jul; 9(7):703-8.
Score: 0.008
-
Progression of Device-Detected Subclinical Atrial Fibrillation and the Risk?of Heart Failure. J Am Coll Cardiol. 2018 06 12; 71(23):2603-2611.
Score: 0.008
-
Comparison of Hyaluronic Acid Gel With (HARDL) and Without Lidocaine (HAJUP) in the Treatment of Moderate-To-Severe Nasolabial Folds: A Randomized, Evaluator-Blinded Study. Dermatol Surg. 2018 06; 44(6):833-840.
Score: 0.008
-
Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care. 1998 Jun; 36(6):778-92.
Score: 0.008
-
Comparison of single- and dual-coil active pectoral defibrillation lead systems. J Am Coll Cardiol. 1998 May; 31(6):1391-4.
Score: 0.008
-
Stroke type and severity in patients with subclinical atrial fibrillation: An analysis from the Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial (ASSERT). Am Heart J. 2018 07; 201:160-163.
Score: 0.008
-
Effect of shock polarity on biphasic defibrillation thresholds using an active pectoral lead system. J Cardiovasc Electrophysiol. 1998 Apr; 9(4):350-4.
Score: 0.008
-
Temporal stability of defibrillation thresholds with an active pectoral lead system. J Cardiovasc Electrophysiol. 1998 Mar; 9(3):240-4.
Score: 0.008
-
The interaction of sex, height, and QRS duration on the effects of cardiac resynchronization therapy on morbidity and mortality: an individual-patient data meta-analysis. Eur J Heart Fail. 2018 04; 20(4):780-791.
Score: 0.008
-
Implications and treatment of atrial fibrillation after cardiothoracic surgery. Curr Opin Cardiol. 1998 Jan; 13(1):20-7.
Score: 0.008
-
Comparison of power- and temperature-guided radiofrequency modification of the atrioventricular node. Polaris Investigator Group. Am J Cardiol. 1997 Dec 01; 80(11):1444-7.
Score: 0.008
-
Strength-duration relationship for human transvenous defibrillation. Circulation. 1997 Nov 18; 96(10):3517-20.
Score: 0.008
-
Lead system optimization for transvenous defibrillation. Am J Cardiol. 1997 Nov 01; 80(9):1163-7.
Score: 0.008
-
Effect of biphasic waveforms on transvenous defibrillation thresholds in patients with coronary artery disease. Am J Cardiol. 1997 Oct 15; 80(8):1098-100.
Score: 0.008
-
Precision Medicine for Cardiac Resynchronization: Predicting Quality of Life Benefits for Individual Patients-An Analysis From 5 Clinical Trials. Circ Heart Fail. 2017 Oct; 10(10).
Score: 0.008
-
Subcutaneous Versus Transvenous Implantable Defibrillator Therapy: A Meta-Analysis of Case-Control Studies. JACC Clin Electrophysiol. 2017 12 26; 3(13):1475-1483.
Score: 0.008
-
Comparison of class Ia/Ib versus class III antiarrhythmic drugs for the suppression of inducible sustained ventricular tachycardia associated with coronary artery disease. Am J Cardiol. 1997 Sep 01; 80(5):591-4.
Score: 0.008
-
Lidocaine-related increase in defibrillation threshold. Anesth Analg. 1997 Aug; 85(2):299-300.
Score: 0.008
-
Biphasic waveforms prevent the chronic rise of defibrillation thresholds with a transvenous lead system. J Am Coll Cardiol. 1997 Jul; 30(1):233-6.
Score: 0.008
-
Clinical predictors of transvenous biphasic defibrillation thresholds. Am J Cardiol. 1997 Jun 15; 79(12):1623-7.
Score: 0.008
-
Distortion of intracardiac electrograms following defibrillator shocks for atrial tachyarrhythmias. Pacing Clin Electrophysiol. 1997 Jun; 20(6):1682-5.
Score: 0.008
-
Effect of waveform tilt on defibrillation thresholds in humans. J Cardiovasc Electrophysiol. 1997 May; 8(5):496-501.
Score: 0.008
-
Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. Eur Heart J. 2017 May 01; 38(17):1339-1344.
Score: 0.008
-
Left Ventricular Architecture, Long-Term Reverse Remodeling, and Clinical Outcome in Mild Heart Failure With Cardiac?Resynchronization: Results From the REVERSE Trial. JACC Heart Fail. 2017 03; 5(3):169-178.
Score: 0.008
-
The acute hemodynamic effects of right ventricular septal pacing in patients with congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1997 Mar 01; 79(5):679-81.
Score: 0.008
-
Chronic rise in monophasic defibrillation thresholds with a transvenous lead system. Am J Cardiol. 1997 Feb 15; 79(4):502-5.
Score: 0.008
-
Clinical predictors of transvenous defibrillation energy requirements. Am J Cardiol. 1997 Jan 15; 79(2):150-3.
Score: 0.007
-
Complications associated with pectoral implantation of cardioverter defibrillators. World-Wide Jewel Investigators. Pacing Clin Electrophysiol. 1997 Jan; 20(1 Pt 2):208-11.
Score: 0.007
-
Performance of the subcutaneous implantable cardioverter-defibrillator in patients with a primary prevention indication with and without a reduced ejection fraction versus patients with a secondary prevention indication. Heart Rhythm. 2017 03; 14(3):367-375.
Score: 0.007
-
Longer Left Ventricular Electric Delay Reduces Mitral Regurgitation After Cardiac Resynchronization Therapy: Mechanistic Insights From the SMART-AV Study (SmartDelay Determined AV Optimization: A Comparison to Other AV Delay Methods Used in Cardiac Resynchronization Therapy). Circ Arrhythm Electrophysiol. 2016 11; 9(11).
Score: 0.007
-
Complications associated with pectoral cardioverter-defibrillator implantation: comparison of subcutaneous and submuscular approaches. Worldwide Jewel Investigators. J Am Coll Cardiol. 1996 Nov 01; 28(5):1278-82.
Score: 0.007
-
Efficacy and safety of procainamide in preventing arrhythmias after coronary artery bypass surgery. Am J Cardiol. 1996 Nov 01; 78(9):975-9.
Score: 0.007
-
Increased Monday incidence of life-threatening ventricular arrhythmias. Experience with a third-generation implantable defibrillator. Circulation. 1996 Sep 15; 94(6):1346-9.
Score: 0.007
-
Effects of an active pectoral-pulse generator shell on defibrillation efficacy with a transvenous lead system. Am J Cardiol. 1996 Sep 01; 78(5):540-3.
Score: 0.007
-
Chronic rise in defibrillation threshold with a hybrid lead system. Am J Cardiol. 1996 Aug 01; 78(3):309-12.
Score: 0.007
-
Effects of waveform and polarity on defibrillation thresholds in humans using a transvenous lead system. Am J Cardiol. 1996 Aug 01; 78(3):313-6.
Score: 0.007
-
Electrophysiologic effects and predictors of success of combination therapy with class Ia and Ib antiarrhythmic drugs for sustained ventricular arrhythmias. Am J Cardiol. 1996 Jul 01; 78(1):47-50.
Score: 0.007
-
Prenatal Fish Oil Supplementation and Allergy: 6-Year Follow-up of a Randomized Controlled Trial. Pediatrics. 2016 06; 137(6).
Score: 0.007
-
Image Quality of Cardiac Magnetic Resonance Imaging in Patients With an Implantable Cardioverter Defibrillator System Designed for the Magnetic Resonance Imaging Environment. Circ Cardiovasc Imaging. 2016 May; 9(5).
Score: 0.007
-
Prebiotic-supplemented partially hydrolysed cow's milk formula for the prevention of eczema in high-risk infants: a randomized controlled trial. Allergy. 2016 05; 71(5):701-10.
Score: 0.007
-
Evaluation of subcutaneous ICD early performance in hypertrophic cardiomyopathy from the pooled EFFORTLESS and IDE cohorts. Heart Rhythm. 2016 05; 13(5):1066-1074.
Score: 0.007
-
The paracaspase MALT1 cleaves HOIL1 reducing linear ubiquitination by LUBAC to dampen lymphocyte NF-?B signalling. Nat Commun. 2015 Nov 03; 6:8777.
Score: 0.007
-
Dual-chamber pacing with a short atrioventricular delay in congestive heart failure: a randomized study. J Am Coll Cardiol. 1995 Oct; 26(4):967-73.
Score: 0.007
-
Effects of Cardiac Resynchronization Therapy on Cardiac Remodeling and Contractile Function: Results From Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE). J Am Heart Assoc. 2015 Sep 11; 4(9):e002054.
Score: 0.007
-
Reduced appropriate implantable cardioverter-defibrillator therapy after cardiac resynchronization therapy-induced left ventricular function recovery: a meta-analysis and systematic review. Eur Heart J. 2015 Nov 01; 36(41):2780-9.
Score: 0.007
-
Novel measure of electrical dyssynchrony predicts response in cardiac resynchronization therapy: Results from the SMART-AV Trial. Heart Rhythm. 2015 Dec; 12(12):2402-10.
Score: 0.007
-
Acute electrophysiologic effects of amiodarone in patients with congestive heart failure. Am J Cardiol. 1995 Jun 01; 75(16):1158-61.
Score: 0.007
-
Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator: 2-Year Results From a Pooled Analysis of the IDE?Study?and?EFFORTLESS Registry. J Am Coll Cardiol. 2015 Apr 28; 65(16):1605-1615.
Score: 0.007
-
Rationale and Design of the Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy Study (LAPTOP-HF). J Card Fail. 2015 Jun; 21(6):479-88.
Score: 0.007
-
The Post-Myocardial Infarction Pacing Remodeling Prevention Therapy (PRomPT) Trial: Design and Rationale. J Card Fail. 2015 Jul; 21(7):601-7.
Score: 0.007
-
Spurious discharges due to late insulation break in endocardial sensing leads for cardioverter defibrillators. Pacing Clin Electrophysiol. 1995 Mar; 18(3 Pt 1):478-81.
Score: 0.007
-
Response to letter regarding article "Temporal relationship between subclinical atrial fibrillation and embolic events". Circulation. 2015 Feb 03; 131(5):e337-8.
Score: 0.007
-
Overdrive pacing for atrial flutter. Am J Cardiol. 1994 Nov 15; 74(10):1021-3.
Score: 0.006
-
Febrile seizures following measles and varicella vaccines in young children in Australia. Vaccine. 2015 Mar 10; 33(11):1412-7.
Score: 0.006
-
Clinical epidemiology and predictors of outcome in children hospitalised with influenza A(H1N1)pdm09 in 2009: a prospective national study. Influenza Other Respir Viruses. 2014 Nov; 8(6):636-45.
Score: 0.006
-
Long-term effectiveness of the combined minute ventilation and patient activity sensors as predictor of heart failure events in patients treated with cardiac resynchronization therapy: Results of the Clinical Evaluation of the Physiological Diagnosis Function in the PARADYM CRT device Trial (CLEPSYDRA) study. Eur J Heart Fail. 2014 Jun; 16(6):663-70.
Score: 0.006
-
Temporal relationship between subclinical atrial fibrillation and embolic events. Circulation. 2014 May 27; 129(21):2094-9.
Score: 0.006
-
High dose oral amiodarone loading exerts important hemodynamic actions in patients with congestive heart failure. J Am Coll Cardiol. 1994 Mar 01; 23(3):560-4.
Score: 0.006
-
Ischemically mediated sustained monomorphic ventricular tachycardia. Resolution with anti-ischemic therapy. Chest. 1993 Nov; 104(5):1613-4.
Score: 0.006
-
Impact of ejection fraction on the clinical response to cardiac resynchronization therapy in mild heart failure. Circ Heart Fail. 2013 Nov; 6(6):1180-9.
Score: 0.006
-
Implantable cardiovertor/defibrillator placement in a patient with amiodarone pulmonary toxicity under thoracic epidural anesthesia. Anesthesiology. 1993 Sep; 79(3):608-11.
Score: 0.006
-
Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator. Circulation. 2013 Aug 27; 128(9):944-53.
Score: 0.006
-
Health insurance and mortality. Evidence from a national cohort. JAMA. 1993 Aug 11; 270(6):737-41.
Score: 0.006
-
An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J. 2013 Dec; 34(46):3547-56.
Score: 0.006
-
A phase IV, open-label study evaluating the use of triple-combination therapy with minocycline HCl extended-release tablets, a topical antibiotic/retinoid preparation and benzoyl peroxide in patients with moderate to severe acne vulgaris. J Drugs Dermatol. 2013 Jun 01; 12(6):619-25.
Score: 0.006
-
Long-term impact of cardiac resynchronization therapy in mild heart failure: 5-year results from the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. Eur Heart J. 2013 Sep; 34(33):2592-9.
Score: 0.006
-
Ezogabine (KCNQ2/3 channel opener) prevents delayed activation of meningeal nociceptors if given before but not after the occurrence of cortical spreading depression. Epilepsy Behav. 2013 Aug; 28(2):243-8.
Score: 0.006
-
Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines. Dermatol Surg. 2013 Apr; 39(4):551-8.
Score: 0.006
-
Ethnic differences in atrial fibrillation identified using implanted cardiac devices. J Cardiovasc Electrophysiol. 2013 Apr; 24(4):381-7.
Score: 0.006
-
Tricyclic overdose causing sustained monomorphic ventricular tachycardia. Am J Cardiol. 1992 Nov 01; 70(13):1226-8.
Score: 0.006
-
Chronic kidney disease and cardiac remodelling in patients with mild heart failure: results from the REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction (REVERSE) study. Eur J Heart Fail. 2012 Dec; 14(12):1420-8.
Score: 0.006
-
2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. Europace. 2012 Sep; 14(9):1236-86.
Score: 0.006
-
2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. Heart Rhythm. 2012 Sep; 9(9):1524-76.
Score: 0.006
-
Palliative care for patients with chronic obstructive pulmonary disease: exploring the landscape. Intern Med J. 2012 Sep; 42(9):1053-7.
Score: 0.006
-
Atrial overdrive pacing to prevent atrial fibrillation: insights from ASSERT. Heart Rhythm. 2012 Oct; 9(10):1667-73.
Score: 0.005
-
Relevance of electrical remodeling in human atrial fibrillation: results of the Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial mechanisms of atrial fibrillation study. Circ Arrhythm Electrophysiol. 2012 Aug 01; 5(4):626-31.
Score: 0.005
-
Sites of left and right ventricular lead implantation and response to cardiac resynchronization therapy observations from the REVERSE trial. Eur Heart J. 2012 Nov; 33(21):2662-71.
Score: 0.005
-
Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012 Jan 12; 366(2):120-9.
Score: 0.005
-
Potential mechanisms underlying the effect of gender on response to cardiac resynchronization therapy: insights from the SMART-AV multicenter trial. Heart Rhythm. 2012 May; 9(5):736-41.
Score: 0.005
-
Acute clinical evaluation of a left ventricular automatic threshold determination algorithm based on evoked response sensing. Pacing Clin Electrophysiol. 2012 Mar; 35(3):348-56.
Score: 0.005
-
Esmolol and ventilatory function in cardiac patients with COPD. Chest. 1991 Nov; 100(5):1215-8.
Score: 0.005
-
Reliability analysis of the resting state can sensitively and specifically identify the presence of Parkinson disease. Neuroimage. 2013 Jul 15; 75:249-261.
Score: 0.005
-
Continuous hemodynamic monitoring in patients with mild to moderate heart failure: results of The Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic Heart Failure (REDUCEhf) trial. Congest Heart Fail. 2011 Sep-Oct; 17(5):248-54.
Score: 0.005
-
Apathy, depression, and motor symptoms have distinct and separable resting activity patterns in idiopathic Parkinson disease. Neuroimage. 2013 Nov 01; 81:484-495.
Score: 0.005
-
Recurrence of extensive injection site reactions following DTPa or dTpa vaccine in children 4-6 years old. Vaccine. 2011 Jun 06; 29(25):4230-7.
Score: 0.005
-
Intraoperative anaphylaxis: an association with latex sensitivity. J Allergy Clin Immunol. 1991 Mar; 87(3):662-6.
Score: 0.005
-
Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). Circulation. 2011 Mar 15; 123(10):1061-72.
Score: 0.005
-
Cardiac resynchronization therapy in asymptomatic or mildly symptomatic heart failure patients in relation to etiology: results from the REVERSE (REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction) study. J Am Coll Cardiol. 2010 Nov 23; 56(22):1826-31.
Score: 0.005
-
Primary results from the SmartDelay determined AV optimization: a comparison to other AV delay methods used in cardiac resynchronization therapy (SMART-AV) trial: a randomized trial comparing empirical, echocardiography-guided, and algorithmic atrioventricular delay programming in cardiac resynchronization therapy. Circulation. 2010 Dec 21; 122(25):2660-8.
Score: 0.005
-
A multi-center randomized proof-of-concept clinical trial applying [?8F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's disease. J Alzheimers Dis. 2010; 22(4):1241-56.
Score: 0.005
-
Cardiac resynchronization induces major structural and functional reverse remodeling in patients with New York Heart Association class I/II heart failure. Circulation. 2009 Nov 10; 120(19):1858-65.
Score: 0.005
-
Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial. J Am Coll Cardiol. 2009 Nov 10; 54(20):1837-46.
Score: 0.005
-
Adverse events arising from a palliative care survey. Palliat Med. 2009 Oct; 23(7):665-9.
Score: 0.004
-
Predictors of placebo response in pooled lamotrigine neuropathic pain clinical trials. Clin J Pain. 2009 Jul-Aug; 25(6):469-76.
Score: 0.004
-
Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol. 2008 Dec 02; 52(23):1834-1843.
Score: 0.004
-
Baseline characteristics of patients randomized in The Resynchronization Reverses Remodeling In Systolic Left Ventricular Dysfunction (REVERSE) study. Congest Heart Fail. 2008 Mar-Apr; 14(2):66-74.
Score: 0.004
-
Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study. J Am Coll Cardiol. 2007 Sep 18; 50(12):1150-7.
Score: 0.004
-
Preventing tomorrow's sudden cardiac death today: part II: Translating sudden cardiac death risk assessment strategies into practice and policy. Am Heart J. 2007 Jun; 153(6):951-9.
Score: 0.004
-
Serial evaluation of atrial tachyarrhythmia burden and frequency after implantation of a dual-chamber cardioverter-defibrillator. J Cardiovasc Electrophysiol. 2005 Jul; 16(7):708-13.
Score: 0.003
-
Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease. Dement Geriatr Cogn Disord. 2005; 20(2-3):120-32.
Score: 0.003
-
Efficacy of transthoracic cardioversion of atrial fibrillation using a biphasic, truncated exponential shock waveform at variable initial shock energies. Am J Cardiol. 2004 Dec 15; 94(12):1572-4.
Score: 0.003
-
Seasonal variation of mortality in the Antiarrhythmics Versus Implantable Defibrillators (AVID) study registry. Heart Rhythm. 2004 Oct; 1(4):435-40.
Score: 0.003
-
Termination of paroxysmal supraventricular tachycardia by tecadenoson (CVT-510), a novel A1-adenosine receptor agonist. J Am Coll Cardiol. 2003 Sep 17; 42(6):1098-102.
Score: 0.003
-
A new pacemaker algorithm for the treatment of atrial fibrillation: results of the Atrial Dynamic Overdrive Pacing Trial (ADOPT). J Am Coll Cardiol. 2003 Aug 20; 42(4):627-33.
Score: 0.003
-
Prevalence of sensing abnormalities in dual chamber implantable cardioverter defibrillators. Ann Noninvasive Electrocardiol. 2003 Jul; 8(3):219-26.
Score: 0.003
-
Effect of an implantable cardioverter defibrillator with atrial detection and shock therapies on patient-perceived, health-related quality of life. Am Heart J. 2003 May; 145(5):841-6.
Score: 0.003
-
Effect of implantable defibrillators on arrhythmic events and mortality in the multicenter unsustained tachycardia trial. Circulation. 2002 Jul 09; 106(2):233-8.
Score: 0.003
-
Postentrainment activation sequence: diagnostic of the supraventricular tachycardia mechanism? J Cardiovasc Electrophysiol. 2002 Apr; 13(4):410-2.
Score: 0.003
-
National study of adverse reactions after vaccination with bacille Calmette-Gu?rin. Clin Infect Dis. 2002 Feb 15; 34(4):447-53.
Score: 0.003
-
Electrical storm presages nonsudden death: the antiarrhythmics versus implantable defibrillators (AVID) trial. Circulation. 2001 Apr 24; 103(16):2066-71.
Score: 0.003
-
Lead- and device-related complications in the antiarrhythmics versus implantable defibrillators trial. Am Heart J. 2001 Jan; 141(1):92-8.
Score: 0.002
-
Assessing the efficacy of a school-based asthma education program for children: a pilot study. Can J Public Health. 2001 Jan-Feb; 92(1):30-4.
Score: 0.002
-
Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 2000 Jun 29; 342(26):1937-45.
Score: 0.002
-
No association between the NOS3 codon 298 polymorphism and Alzheimer's disease in a sample from the United States. Ann Neurol. 2000 May; 47(5):687.
Score: 0.002
-
Gender-specific association of the angiotensin converting enzyme gene with Alzheimer's disease. Neurosci Lett. 2000 Feb 25; 280(3):215-9.
Score: 0.002
-
Alzheimers disease is not associated with the hypertension genetic risk factors PLA(2) or G protein beta3, either independently or interactively with apolipoprotein E. Am J Med Genet. 1999 Oct 15; 88(5):465-8.
Score: 0.002
-
Comparison of the sedation and recovery profiles of Ro 48-6791, a new benzodiazepine, and midazolam in combination with meperidine for outpatient endoscopic procedures. Anesth Analg. 1999 Oct; 89(4):893-8.
Score: 0.002
-
The alpha-2 macroglobulin gene is not associated with Alzheimer's disease in a case-control sample. Neurosci Lett. 1999 Aug 06; 270(3):133-6.
Score: 0.002
-
No genetic association between polymorphisms in the Tau gene and Alzheimer's disease in clinic or population based samples. Neurosci Lett. 1999 May 14; 266(3):193-6.
Score: 0.002
-
Prediction of sustained ventricular tachycardia inducible by programmed stimulation in patients with coronary artery disease. Utility of clinical variables. Circulation. 1999 Apr 13; 99(14):1843-50.
Score: 0.002
-
The -491A/T apolipoprotein E promoter polymorphism association with Alzheimer's disease: independent risk and linkage disequilibrium with the known APOE polymorphism. Neurosci Lett. 1998 Aug 14; 252(2):95-8.
Score: 0.002
-
The butyrylcholinesterase gene is neither independently nor synergistically associated with late-onset AD in clinic- and community-based populations. Neurosci Lett. 1998 Jun 19; 249(2-3):115-8.
Score: 0.002
-
Refusal of out-of-hospital medical care: effect of medical-control physician assertiveness on transport rate. Acad Emerg Med. 1998 Jan; 5(1):4-8.
Score: 0.002
-
Gender differences in presentation, management, and cardiac event-free survival in patients with syncope. Am J Cardiol. 1997 Nov 01; 80(9):1183-7.
Score: 0.002
-
No association between the very low density lipoprotein receptor gene and late-onset Alzheimer's disease nor interaction with the apolipoprotein E gene in population-based and clinic samples. Genet Epidemiol. 1997; 14(3):299-305.
Score: 0.002
-
Use of care and subsequent mortality: the importance of gender. Health Serv Res. 1996 Aug; 31(3):347-63.
Score: 0.002
-
Intranasal fluticasone propionate versus loratadine in the treatment of adolescent patients with seasonal allergic rhinitis. J Allergy Clin Immunol. 1996 Feb; 97(2):588-95.
Score: 0.002
-
Prognostic importance of the length of ventricular tachycardia in patients with nonischemic congestive heart failure. Am Heart J. 1995 Sep; 130(3 Pt 1):489-93.
Score: 0.002
-
Prognostic value of the signal-averaged electrocardiogram and a prolonged QRS in ischemic and nonischemic cardiomyopathy. Am J Cardiol. 1995 Mar 01; 75(7):460-4.
Score: 0.002
-
Acute hemodynamic effects of atrio-biventricular pacing in humans. Ann Thorac Surg. 1995 Feb; 59(2):294-300.
Score: 0.002
-
A home-based geriatric assessment, follow-up and health promotion program: design, methods, and baseline findings from a 3-year randomized clinical trial. Aging (Milano). 1994 Apr; 6(2):105-20.
Score: 0.002
-
Health insurance and subjective health status: data from the 1987 National Medical Expenditure survey. Am J Public Health. 1993 Sep; 83(9):1295-9.
Score: 0.001
-
Racial differentials in the identification of hypercholesterolemia. J Fam Pract. 1993 Apr; 36(4):425-30.
Score: 0.001
-
Delinquency as defense. Am J Orthopsychiatry. 1972 Apr; 42(3):463-79.
Score: 0.001
-
Electrophysiologic response to moricizine in patients with sustained ventricular arrhythmias. Ann Intern Med. 1992 Mar 01; 116(5):382-7.
Score: 0.001
-
Hypomagnesemia is a frequent finding in the emergency department in patients with chest pain. Arch Intern Med. 1991 Nov; 151(11):2185-90.
Score: 0.001
-
Barriers to cholesterol testing in a rural community. J Fam Pract. 1991 Jun; 32(6):614-8.
Score: 0.001
-
Retroperitoneal cystic lymphangioma. AJR Am J Roentgenol. 1983 Apr; 140(4):733-4.
Score: 0.001